Cargando…

A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China

BACKGROUND AND OBJECTIVE: Currently, the detection rates of methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS) in the blood cultures of neonates with sepsis exceed the national average drug resistance level, and vancomycin and linezolid are the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Linjun, Ding, Leyun, Tang, Lian, Yang, Zuming, Wu, Dan, Wang, Wenjuan, Mao, Juehui, Shi, Lu, Liu, Chun, Duan, Lufen, Xu, Jinhui, Zhou, Qin, Sun, Jiantong, Ding, Xinyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357666/ https://www.ncbi.nlm.nih.gov/pubmed/37468855 http://dx.doi.org/10.1186/s12913-023-09628-9

Ejemplares similares

A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study
por: Duan, Lufen, et al.
Publicado: (2022)

1656. Evaluation of Using Oxacillin versus Vancomycin for Empiric Therapy of Late-Onset Neonatal Sepsis in NICU
por: Lien, Tsung-Chi, et al.
Publicado: (2023)

Decreasing Vancomycin Utilization in the NICU by Optimizing Treatment Decisions in Suspected Late Onset Sepsis
por: Maffei, Diana, et al.
Publicado: (2017)

The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis
por: Lu, Guangxian, et al.
Publicado: (2021)

The potential value of plasma receptor interacting protein 3 in neonates with culture-positive late-onset sepsis
por: Gao, Chuchu, et al.
Publicado: (2021)

Biomarkers for late-onset neonatal sepsis
por: Polin, Richard A, et al.
Publicado: (2010)

Methicillin-Resistant Staphylococcus capitis with Reduced Vancomycin Susceptibility Causes Late-Onset Sepsis in Intensive Care Neonates
por: Rasigade, Jean-Philippe, et al.
Publicado: (2012)

1144. Evaluation of Nafcillin vs. Vancomycin as Empiric Therapy for Late-Onset Sepsis in the Neonatal Intensive Care Unit
por: Magers, Jacqueline, et al.
Publicado: (2019)

Linezolid vs Vancomycin in Induced Thrombocytopenia
por: Al-Harbi, Dimah, et al.
Publicado: (2022)

Late-onset neonatal sepsis: recent developments
por: Dong, Ying, et al.
Publicado: (2015)

Late-onset neonatal sepsis in Suzhou, China
por: Pan, Tao, et al.
Publicado: (2020)

Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study
por: Xu, Jinhui, et al.
Publicado: (2022)

Biomarkers for Late-Onset Neonatal Sepsis: Cytokines and Beyond
por: Ng, Pak C., et al.
Publicado: (2010)

Early Diagnostic Markers of Late-Onset Neonatal Sepsis
por: Gatseva, Preslava, et al.
Publicado: (2023)

Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains
por: Aktas, Gulseren
Publicado: (2020)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis
por: Babalola, Olufemi Emmanuel
Publicado: (2020)

476 Heterogeneous Vancomycin-Intermediate Coagulase-Negative Staphylococci in Neonates: Does treatment with Linezolid improve outcomes?
por: Blanchard, Ana Chelène, et al.
Publicado: (2014)

Emerging antimicrobial resistance in early and late-onset neonatal sepsis
por: Mohsen, Lamiaa, et al.
Publicado: (2017)

Late-Onset Neonatal Sepsis in a Patient with Covid-19
por: Coronado Munoz, Alvaro, et al.
Publicado: (2020)

The Role and Validity of Diagnostic Biomarkers in Late-Onset Neonatal Sepsis
por: Mwesigye, Patience, et al.
Publicado: (2021)

The Impact of a Multifaceted Pharmacist-Led Antimicrobial Stewardship Program on Antibiotic Use: Evidence From a Quasi-Experimental Study in the Department of Vascular and Interventional Radiology in a Chinese Tertiary Hospital
por: Xu, Jinhui, et al.
Publicado: (2022)

Early Diagnosis of Late-Onset Neonatal Sepsis Using a Sepsis Prediction Score
por: Sofouli, Georgia Anna, et al.
Publicado: (2023)

Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
por: Narayanan, Navaneeth, et al.
Publicado: (2019)

1341. Blood Volume Collected for Blood Cultures in Infants with Suspected Neonatal Sepsis in the NICU
por: Altez, Maria S Rueda, et al.
Publicado: (2020)

Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis
por: Bode, Christian, et al.
Publicado: (2015)

1354. Reducing vancomycin utilization rate in a level 4 NICU
por: Chang, Millie R, et al.
Publicado: (2020)

Outcome of Late-onset Neonatal Sepsis at a Tertiary Hospital in Oman
por: Abdellatif, Mohamed, et al.
Publicado: (2019)

Comparative Assessment of Cytokine Pattern in Early and Late Onset of Neonatal Sepsis
por: Khaertynov, Kh. S., et al.
Publicado: (2017)

Prevention of neonatal late-onset sepsis: a randomised controlled trial
por: Alcock, Gary, et al.
Publicado: (2017)

Diagnostic utility of procalcitonin as a biomarker for late-onset neonatal sepsis
por: Liu, Chunmei, et al.
Publicado: (2020)

Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis
por: Al-Mouqdad, Mountasser, et al.
Publicado: (2021)

Plasma D-dimer level in early and late-onset neonatal sepsis
por: Al-Biltagi, Mohammed, et al.
Publicado: (2022)

Carboxyhemoglobin Levels in Preterm Neonatal Late-Onset Sepsis: to Predict or not to Predict
por: Vardar, Gonca, et al.
Publicado: (2023)

Induction of labor and early-onset Sepsis guidelines: impact on NICU admissions in Erie County, NY
por: Dumpa, Vikramaditya, et al.
Publicado: (2019)

Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus
por: Pontefract, Benjamin Alan, et al.
Publicado: (2020)

Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2021)

Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
por: Wingler, Mary Joyce, et al.
Publicado: (2021)

Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future
por: Matrat, Lucie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aav8il3jhgnltlevjcm8no6ktr